Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Consensus PT from Analysts
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have been given an average rating of “Buy” by the six brokerages that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average […]
More Stories
Look to Tech for Dividends
By Anne Kates Smith, Kiplinger’s Personal Finance, distributed by Tribune News Service Investors searching for dividends rarely look among the...
Understand Chronic Inflammation and 6 Ways To Reduce It
By Emma Suttie, D. Ac., AP Chronic inflammation is like a silent intruder within your body—quietly stoking the embers of...
AAR (NYSE:AIR) Announces Quarterly Earnings Results, Beats Expectations By $0.03 EPS
AAR (NYSE:AIR – Get Free Report) announced its quarterly earnings data on Monday. The aerospace company reported $0.85 earnings per...
Lebanon escalation: UN boosts support at border with Syria
The serious escalation in hostilities between Hezbollah and Israel has forced “tens of thousands” of people to flee their homes...
Trump Briefed on Specific Iran Threats to Assassinate Him
By Janice Hisle Former President Donald Trump, who has already survived two assassination attempts, has received a briefing on “real...
Judge Declares NYC’s Data-Sharing Law for Food Delivery Apps Unconstitutional
By Katabella Roberts A New York City COVID-era law requiring food delivery companies to share various customer data with restaurants...